Skip to main content
evidena care

Basics

THC and CBD: the difference and what the ratio means

THC and CBD come from the same plant but act differently. What the THC-CBD ratio of a medicine tells you and what research knows about it.

Key points

  • THC is a partial agonist at the CB1 receptor in the brain. This is the basis of the high, but also of side effects such as memory problems and impaired fitness to drive.
  • CBD does not cause a high and has hardly any activating effect at CB1. In the laboratory, it dampened the signalling of THC at the receptor; in humans, it is active at many other targets.
  • The THC-CBD ratio describes how much THC a preparation contains compared with CBD. It says nothing about the absolute quantity.
  • Whether CBD weakens the effect of THC is not established. A review found mixed results and no clear dose-response relationship.
  • Which preparation and which composition can be considered is decided by your doctor case by case.

THC and CBD are the two best-known active substances of the cannabis plant. The difference: THC (tetrahydrocannabinol) activates the cannabinoid receptor CB1 in the brain and causes a high. CBD (cannabidiol) does not cause a high and acts at other sites in the body.1,2

The THC-CBD ratio of a preparation indicates how much THC it contains compared with CBD. Whether a particular ratio brings advantages in a particular condition is not established. Which medicine can be considered is decided by your doctor.4

What is THC? Action at the CB1 receptor

The body has its own signalling system, the endocannabinoid system. Its most important receptors are called CB1 and CB2. CB1 is found mainly in the nervous system, CB2 mainly in cells of the immune system. Among other things, the endocannabinoid system influences how nerve cells pass on signals.2

At CB1 and CB2, THC is a so-called partial agonist: it binds to the receptor and activates it, but not to the maximum. How strong the effect is depends on how many receptors are present in a tissue and how active the body’s own system is at the time.1 Cannabinoid receptors are the main target of THC, the intoxicating constituent of cannabis.2

CB1 explains typical effects and side effects of THC: the high, psychosis-like effects, memory problems and impaired fitness to drive. With repeated use, tolerance develops.1,6,7 You will find more on undesirable effects in the article Cannabis side effects.

What is CBD? No high, many targets

CBD has hardly any activating effect at CB1. In cell and tissue experiments, CBD inhibited the effect of other substances at CB1 and CB2 surprisingly strongly.1 A laboratory study in cell cultures described CBD as a so-called negative allosteric modulator of CB1: CBD binds at a different site on the receptor and thereby weakens the signalling of THC and of the body’s own cannabinoids.3

These are laboratory findings. Whether they play a role in humans at usual amounts is an open question. In addition, CBD acts at numerous other targets outside the endocannabinoid system. Which of them is responsible for which effect has not been conclusively clarified.1,3

“Not intoxicating” does not mean “without effect”. THC and CBD are broken down in the liver; CBD can inhibit the breakdown of other medicines there and can therefore cause interactions.11 This is described in the article Interactions of THC and CBD with medicines.

THC vs. CBD at a glance

THC CBD
Action at CB1 partial agonist, activating hardly activating, inhibiting in the laboratory
High yes no
Fitness to drive impaired in studies not measurably changed in a driving study
Legal status in Switzerland narcotic from 1% total THC not a narcotic if below 1% THC

The information on fitness to drive comes from a study of 26 healthy people who used cannabis occasionally.7 For the legal status, see the glossary.

What does the THC-CBD ratio mean?

The ratio describes the amounts of the two active substances relative to each other. “1:1” means as much THC as CBD. “1:20” means twenty times more CBD than THC. Preparations are then described as THC-dominant, balanced or CBD-dominant.

Two points are important. First, the ratio says nothing about the absolute amount: a 1:1 preparation can contain little or a lot of both active substances. Second, the effect also depends on how the preparation is taken. When swallowed, the effect of THC sets in more slowly than when inhaled, and absorption into the blood varies more.9 The forms are described in the article Dosage forms of medical cannabis.

One example from Switzerland is Sativex. The oromucosal spray contains a cannabis extract with THC and CBD and is authorised by Swissmedic as an add-on therapy for moderate and severe spasticity in multiple sclerosis.10 Other cannabis medicines are made by the pharmacy as a magistral preparation, with the composition prescribed by the doctor.

Does CBD weaken the effect of THC? What studies show

The idea that CBD cushions undesirable effects of THC is widespread. However, the evidence is inconsistent.

  • Evidence for: in a study with 48 healthy people, participants first received 600 mg of CBD or a placebo and then THC intravenously. In the CBD group, clear psychotic symptoms occurred less often, and paranoia and memory problems were less pronounced.5
  • Evidence against: in a study with 48 adolescents and adults who inhaled cannabis, participants received THC alone or with three times the amount of CBD. The additional CBD changed neither the experience of the high nor the memory impairment nor the psychosis-like effects of THC.6
  • Fitness to drive: in the driving study, THC-dominant and balanced cannabis impaired lane keeping to about the same extent 40 to 100 minutes after inhalation. Adding the same amount of CBD therefore did not prevent this.7
  • Dependence on amount: in a study with 36 participants, they received 8 mg of THC inhaled, alone or with 4 mg or 400 mg of CBD. The low amount of CBD intensified the high, the high amount weakened it. The intensifying effect was more pronounced in people who rarely used cannabis.8

A systematic review summarised 16 studies with 466 participants. CBD weakened some effects of THC in several studies, but not consistently. Dose, route of administration and THC-CBD ratio differed widely between the studies, and no clear dose-response relationship emerged.4

Who decides on THC, CBD and the ratio?

The doctor chooses the preparation and composition after an assessment. Factors include your symptoms, pre-existing conditions, other medicines, your experience and whether you drive. THC can trigger psychosis-like symptoms, as the studies described above show. With pre-existing mental illness, it must therefore be weighed particularly carefully; more on this in the article Cannabis medicine despite a pre-existing mental illness.5,6

Do not change the preparation or amount yourself, not even to adjust the ratio. Discuss effects and side effects with your doctor.

How it works at evidena

At evidena, the doctor decides whether a cannabis medicine can be considered for you and which composition is prescribed. A narcotics prescription must be filled within one month. The quantity prescribed generally covers one month, in justified cases at most three months. The process is described on the How it works page.

You can book an appointment at https://portal.evidena.care/appointments. We answer questions via WhatsApp or at info@evidena.care.

Conclusion

THC activates the CB1 receptor and causes a high; CBD does neither and acts via other pathways. The THC-CBD ratio only describes the amounts relative to each other. According to current evidence, it is not established whether CBD weakens the effect of THC, and no ratio that is “right” for particular conditions can be derived from it.

Frequently asked questions

What is the difference between THC and CBD?

THC activates the CB1 receptor in the brain and causes a high. CBD does not cause a high, has hardly any activating effect at CB1 and acts on other targets.

What does the THC-CBD ratio mean?

It indicates how much THC a preparation contains compared with CBD, for example 1:1 for equal amounts. It says nothing about the total amount of active substance.

Does CBD protect against the side effects of THC?

This is not established. Some studies found less anxiety or paranoia, others no difference. A review describes the results as mixed.

Which ratio is the right one for my symptoms?

There is no universal answer. Whether a cannabis medicine, and which one, can be considered is decided by your doctor after an assessment.

Can I drive with CBD?

In a driving study, CBD-dominant cannabis did not measurably change lane keeping, but THC-containing cannabis did. For THC, zero tolerance applies in road traffic, with an exception for medically prescribed THC, provided you are fit to drive.

Your situation is individual

Discuss your questions with a doctor.

Book a consultation

Sources

  1. Pertwee RG. The diverse CB1 and CB2 receptor pharmacology of three plant cannabinoids: delta9-tetrahydrocannabinol, cannabidiol and delta9-tetrahydrocannabivarin. Br J Pharmacol. 2008;153(2):199-215. doi:10.1038/sj.bjp.0707442
  2. Lu HC, Mackie K. Review of the Endocannabinoid System. Biol Psychiatry Cogn Neurosci Neuroimaging. 2021;6(6):607-615. doi:10.1016/j.bpsc.2020.07.016
  3. Laprairie RB et al. Cannabidiol is a negative allosteric modulator of the cannabinoid CB1 receptor. Br J Pharmacol. 2015;172(20):4790-4805. doi:10.1111/bph.13250
  4. Freeman AM et al. How does cannabidiol (CBD) influence the acute effects of delta-9-tetrahydrocannabinol (THC) in humans? A systematic review. Neurosci Biobehav Rev. 2019;107:696-712. doi:10.1016/j.neubiorev.2019.09.036
  5. Englund A et al. Cannabidiol inhibits THC-elicited paranoid symptoms and hippocampal-dependent memory impairment. J Psychopharmacol. 2013;27(1):19-27. doi:10.1177/0269881112460109
  6. Lawn W et al. The acute effects of cannabis with and without cannabidiol in adults and adolescents: A randomised, double-blind, placebo-controlled, crossover experiment. Addiction. 2023;118(7):1282-1294. doi:10.1111/add.16154
  7. Arkell TR et al. Effect of Cannabidiol and Δ9-Tetrahydrocannabinol on Driving Performance: A Randomized Clinical Trial. JAMA. 2020;324(21):2177-2186. doi:10.1001/jama.2020.21218
  8. Solowij N et al. A randomised controlled trial of vaporised Δ9-tetrahydrocannabinol and cannabidiol alone and in combination in frequent and infrequent cannabis users: acute intoxication effects. Eur Arch Psychiatry Clin Neurosci. 2019;269(1):17-35. doi:10.1007/s00406-019-00978-2
  9. Huestis MA. Human cannabinoid pharmacokinetics. Chem Biodivers. 2007;4(8):1770-1804. doi:10.1002/cbdv.200790152
  10. Fachinformation Sativex, Rubrik «Indikationen/Anwendungsmöglichkeiten», Swissmedicinfo (accessed 13 November 2026)
  11. Lucas CJ et al. The pharmacokinetics and the pharmacodynamics of cannabinoids. Br J Clin Pharmacol. 2018;84(11):2477-2482. doi:10.1111/bcp.13710

Written by evidena.care editorial team · Published 13 November 2026 · Reviewed 13 November 2026

This article is general information and does not replace medical advice. Whether cannabis therapy is an option for you is decided by a doctor in a personal consultation.